Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) traded down 5.9% during trading on Friday . The stock traded as low as $0.5647 and last traded at $0.5647. 941 shares were traded during mid-day trading, a decline of 97% from the average session volume of 29,569 shares. The stock had previously closed at $0.60.
Defence Therapeutics Stock Down 5.9%
The firm’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.54.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Further Reading
- Five stocks we like better than Defence Therapeutics
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Do you know what Amazon is planning for January 1?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
